[1]沈季敏,刘 欣,吴金菊.骨髓增生异常综合征患者临床特征分析[J].医学信息,2018,31(18):49-52.[doi:10.3969/j.issn.1006-1959.2018.18.016]
　SHEN Ji-min,LIU Xin,WU Jin-ju.Analysis of Clinical Features of Patients with Myelodysplastic Syndrome[J].Journal of Medical Information,2018,31(18):49-52.[doi:10.3969/j.issn.1006-1959.2018.18.016]
点击复制

骨髓增生异常综合征患者临床特征分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年18期
页码:
49-52
栏目:
论著
出版日期:
2018-09-15

文章信息/Info

Title:
Analysis of Clinical Features of Patients with Myelodysplastic Syndrome
文章编号:
1006-1959（2018）18-0049-04
作者:
沈季敏; 刘 欣; 吴金菊
安徽医科大学附属省立医院血液科/中国科技大学附属第一医院，安徽 合肥 230001
Author(s):
SHEN Ji-min; LIU Xin; WU Jin-ju
Department of Hematology,Provincial Hospital Affiliated to Anhui Medical University/the First Affiliated Hospital,University of Science and Technology of China,Hefei 230001,Anhui,China
关键词:
骨髓增生异常综合征; WHO 分型; 临床特征
Keywords:
Key words：Myelodysplastic syndrome; WHO classification; Clinical features
分类号:
R551.3
DOI:
10.3969/j.issn.1006-1959.2018.18.016
文献标志码:
A
摘要:
目的 探讨细胞形态学检查、流式细胞术、细胞遗传学对MDS诊断分型的作用。方法 以2016年WHO对MDS诊断分型标准为主要参考，回顾性分析安徽医科大学附属安徽省立医院2013年5月~2017年的12月收治住院的120例成人MDS患者的临床症状、血常规、骨髓细胞学、骨髓病理、免疫表型、细胞遗传学方面的特点。结果 120例MDS患者，根据2016年WHO分类，有2例（1.67%）患者符合MDS伴单系病态造血 (MDS-SLD)；有27例（22.50%）患者符合MDS伴多系病态造血 (MDS-MLD),各有3例（2.50%）和4例（3.33%）患者符合MDS伴环状铁粒幼红细胞伴单系发育异常（MDS-RS-SLD）和MDS伴环状铁粒幼红细胞伴多系发育异常（MDS-RS-MLD）,各有 34例（28.33%）和43例（35.83%）是MDS-EB-1和MDS-EB-2；2例（1.67%）单纯5q-的MDS；有5例（4.17%）患者MDS未分类。结论 骨髓细胞形态学和外周血指标仍是MDS诊断的金标准，临床症状、血常规、骨髓细胞学、骨髓病理、免疫表型、细胞遗传学的综合考虑更有利于MDS的分型诊断，并对治疗、预后判断有重要指导价值。
Abstract:
Abstract：Objective To investigate the role of cell morphology,flow cytometry and cytogenetics in the diagnosis of MDS.Methods The 2016 WHO reference classification criteria for MDS was used as the main reference.Retrospective analysis of clinical symptoms, blood routine,bone marrow cytology,bone marrow pathology,immunophenotype,cytogenetics of 120 adult MDS patients admitted to Anhui Provincial Hospital of Anhui Medical University from May 2013 to December 2017 aspects of the characteristics.Results In 120 patients with MDS,according to the 2016 WHO classification,2 patients(1.67%)were eligible for MDS with monosomic hematopoiesis(MDS-SLD);27 patients(22.50%)were eligible for MDS with multiline morbid hematopoiesis(MDS-MLD),3 patients (2.50%)and 4 patients(3.33%)were eligible for MDS with annular iron granulocytes with monophyletic dysplasia(MDS-RS-SLD)and MDS with annular iron granulocytes Multiple line dysplasia(MDS-RS-MLD),34 cases(28.33%)and 43 cases(35.83%)were MDS-EB-1 and MDS-EB-2,respectively;2 cases(1.67%)were simple 5q-MDS;5 patients(4.17%)had unclassified MDS.Conclusion The morphology of bone marrow cells and peripheral blood markers are still the gold standard for the diagnosis of MDS.The comprehensive consideration of clinical symptoms,blood routine,bone marrow cytology,bone marrow pathology,immunophenotype and cytogenetics is more conducive to the diagnosis of MDS.It has important guiding value for treatment and prognosis.

参考文献/References:


[1]Arber DA,Orazi A,Hasserjian R,et al.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J].Blood,2016,127(20):2391-2405.
[2]Dao KHT.Myelodysplastic Syndromes:Updates and Nuances[J].Medical Clinics of North America,2017,101(2):333-350.
[3]Font P,Subira D,Matarraz S,et al.Multicenter comparison of CD34+myeloid cell count by flow cytometry in low-risk myelodysplastic syndrome.Is it feasible[J].Cytometry B Clin Cytom,2017,55(1):98-99.
[4]Aa VDL,Alhan C,Béné MC,et al.Standardization of flow cytometry in myelodysplastic syndromes:report from the first European Leukemia net working conference on flow cytometry in myelodysplastic syndromes[J].Haematologica,2009,94(8):1124-1134.
[5]Lin J,Chen S,Zhao Z,et al.CD123 is a useful immunohistochemical marker to facilitate diagnosis of acute graft-versus-host disease in colon [J].Human Pathology,2013,44(10):2075-2080.
[6]李锦,何广胜.骨髓增生异常综合征病态造血的流式细胞术检测[J].中国实验血液学杂志,2013, 21(4):1069-1072.
[7]茹晓,张凌岩,李英.骨髓增生异常综合征染色体畸变研究进展[J].中国实验血液学杂志,2015, 23(5):1509-1512.
[8]安利,江明.114例骨髓增生异常综合征的染色体核型与预后分析[J].中山大学学报(医学科学版),2014,35(4):575-578.
[9]刘秋艳,王燕,龙珍珠玛,等.骨髓增生异常综合征转化为急性白血病的高危因素分析[J].临床血液学杂志,2017,30(4):524-526.
[10]肖志坚.骨髓增生异常综合征的精准诊断与治疗:现况与问题[J].临床血液学杂志,2017,30(3):339-341.

相似文献/References:

[1]曾 庆,陆嘉惠,周永明.地西他滨治疗骨髓增生异常综合征研究进展[J].医学信息,2019,32(09):32.[doi:10.3969/j.issn.1006-1959.2019.09.011]
　ZENG Qing,LU Jia-hui,ZHOU Yong-ming.Progress in the Study of Decitabine in the Treatment of Myelodysplastic Syndrome[J].Journal of Medical Information,2019,32(18):32.[doi:10.3969/j.issn.1006-1959.2019.09.011]
[2]楼 芸,周永明,朱文伟.骨髓间充质干细胞异常在MDS发病机制中的研究[J].医学信息,2020,33(06):24.[doi:10.3969/j.issn.1006-1959.2020.06.008]
　LIU Yin,HE Qi-hong,YU Lin-song,et al.Study of Bone Marrow Mesenchymal Stem Cell Abnormalities in the Pathogenesis of MDS[J].Journal of Medical Information,2020,33(18):24.[doi:10.3969/j.issn.1006-1959.2020.06.008]
[3]刘华志,王春森.骨髓增生异常综合征突变基因与预后关系的研究现状[J].医学信息,2022,35(02):51.[doi:10.3969/j.issn.1006-1959.2022.02.013]
　LIU Hua-zhi,WANG Chun-sen.Research Status of Relationship Between Mutation Gene and Prognosis inMyelodysplastic Syndrome[J].Journal of Medical Information,2022,35(18):51.[doi:10.3969/j.issn.1006-1959.2022.02.013]
[4]汪 梅,李 丽,任咏惠,等.去甲基化药物联合预激方案在骨髓增生异常综合征中的应用[J].医学信息,2022,35(06):41.[doi:10.3969/j.issn.1006-1959.2022.06.010]
　WANG Mei,LI Li,REN Yong-hui,et al.Application of Demethylated Drugs Combined with Preexcitation Regimen in Myelodysplastic Syndrome[J].Journal of Medical Information,2022,35(18):41.[doi:10.3969/j.issn.1006-1959.2022.06.010]
[5]赵崇山,王宁方.脾脏硬度对初发骨髓增生异常综合征患者预后的影响[J].医学信息,2022,35(07):88.[doi:10.3969/j.issn.1006-1959.2022.07.021]
　ZHAO Chong-shan,WANG Ning-fang.Effect of Spleen Stiffness Measurement on Prognosis of Patients with Primary Myelodysplastic Syndrome[J].Journal of Medical Information,2022,35(18):88.[doi:10.3969/j.issn.1006-1959.2022.07.021]

更新日期/Last Update: 2018-09-15